RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity.
PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肿瘤来源的 PCSK9 在黑色素瘤发病机制中发挥关键作用。PCSK9 的致癌作用与肿瘤内胆固醇积累相关。PCSK9 系统性影响免疫系统,促进黑色素瘤免疫逃逸。源自 PCSK9 网络的新型生物标志物有效预测了 ICB 治疗反应。
PCSK9调节胆固醇稳态并促进肿瘤发生。然而,这两种作用的相关性以及PCSK9在黑色素瘤和其他癌症中致癌作用的机制仍不清楚。
使用TCGA数据集分析PCSK9与黑色素瘤的关联。将空载体(EV)、PCSK9、功能获得型(D374Y)和功能缺失型(Q152H)PCSK9突变体稳定表达于小鼠黑色素瘤B16细胞中,并使用同基因C57BL/6和Pcsk9 -/-小鼠研究其对B16细胞来源的体外和体内肿瘤发生的影响。测定肿瘤内胆固醇蓄积。对各个肿瘤类型进行RNA-seq。差异表达基因(DEGs)来源于B16 PCSK9、B16 D374Y或B16 Q152H肿瘤与B16 EV同种移植瘤的比较,并分析通路改变。
PCSK9表达及其网络与黑色素瘤患者的生存概率呈负相关。PCSK9在体外促进B16细胞增殖、迁移和软琼脂生长,在体内促进C57BL/6小鼠肿瘤形成,并以反映其对低密度脂蛋白受体(LDLR)调控的方式促进瘤内胆固醇积累:Q152H、EV、PCSK9和D374Y。在D374Y肿瘤中,肿瘤相关T细胞、CD8+ T细胞和NK细胞显著增加,同时多个免疫检查点、IFNγ以及与T细胞功能障碍相关的143个基因上调。D374Y差异表达基因与PCSK9差异表达基因之间重叠的36个基因预测黑色素瘤预后不良和对免疫检查点阻断(ICB)治疗的耐药性。CYTH4、DENND1C、AOAH、TBC1D10C、EPSTI1、GIMAP7和FASL(FAS配体)是ICB治疗的新型预测因子,并在黑色素瘤及30种人类癌症中与多个免疫检查点显示高度相关性。我们观察到FAS配体是ICB治疗最稳健的生物标志物之一,并构建了两个新型有效的多基因组合用于预测ICB治疗反应。由B16 EV、PCSK9、D374Y和Q152H产生的同种移植瘤特征在C57BL/6和Pcsk9-/-小鼠中保持可比。
PCSK9 regulates cholesterol homeostasis and promotes tumorigenesis. However, the relevance of these two actions and the mechanisms underlying PCSK9's oncogenic roles in melanoma and other cancers remain unclear.
PCSK9's association with melanoma was analysed using the TCGA dataset. Empty vector (EV), PCSK9, gain-of-function (D374Y), and loss-of-function (Q152H) PCSK9 mutant were stably-expressed in murine melanoma B16 cells and studied for impact on B16 cell-derived oncogenesis in vitro and in vivo using syngeneic C57BL/6 and Pcsk9 -/- mice. Intratumoral accumulation of cholesterol was determined. RNA-seq was performed on individual tumor types. Differentially-expressed genes (DEGs) were derived from the comparisons of B16 PCSK9, B16 D374Y, or B16 Q152H tumors to B16 EV allografts and analysed for pathway alterations.
PCSK9 expression and its network negatively correlated with the survival probability of patients with melanoma. PCSK9 promoted B16 cell proliferation, migration, and growth in soft agar in vitro, formation of tumors in C57BL/6 mice in vivo, and accumulation of intratumoral cholesterol in a manner reflecting its regulation of the low-density lipoprotein receptor (LDLR): Q152H, EV, PCSK9, and D374Y. Tumor-associated T cells, CD8 + T cells, and NK cells were significantly increased in D374Y tumors along with upregulations of multiple immune checkpoints, IFNγ, and 143 genes associated with T cell dysfunction. Overlap of 36 genes between the D374Y DEGs and the PCSK9 DEGs predicted poor prognosis of melanoma and resistance to immune checkpoint blockade (ICB) therapy. CYTH4, DENND1C, AOAH, TBC1D10C, EPSTI1, GIMAP7, and FASL (FAS ligand) were novel predictors of ICB therapy and displayed high level of correlations with multiple immune checkpoints in melanoma and across 30 human cancers. We observed FAS ligand being among the most robust biomarkers of ICB treatment and constructed two novel and effective multigene panels predicting response to ICB therapy. The profiles of allografts produced by B16 EV, PCSK9, D374Y, and Q152H remained comparable in C57BL/6 and Pcsk9 -/- mice.
Tumor-derived PCSK9 plays a critical role in melanoma pathogenesis. PCSK9's oncogenic actions are associated with intratumoral cholesterol accumulation. PCSK9 systemically affects the immune system, contributing to melanoma immune evasion. Novel biomarkers derived from the PCSK9-network effectively predicted ICB therapy responses.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。